GRANT NO: DAMD17-94-J-4216

TITLE: Outcome After Prophylactic Mastectomy in Individuals at High Risk for Breast Cancer: A Combined Clinical Biological Study

PRINCIPAL INVESTIGATOR(S): Doctor Lynn Hartmann
                                 Doctor Robert Jenkins

CONTRACTING ORGANIZATION: Mayo Foundation
                                 Rochester, Minnesota 55905

REPORT DATE: September 1, 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                                 Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Outcome After Prophylactic Mastectomy in Individuals at High Risk for Breast Cancer: A Combined Clinical-Biologic Study

Doctor Lynn Hartman
Doctor Robert Jenkins

Mayo Foundation
Rochester, Minnesota 55905

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for public release; distribution unlimited

Both the clinical and laboratory phases of this work are proceeding on schedule. We have reviewed the medical records of 782 individuals, confirming that 92 percent of them indeed had a mastectomy performed with prophylactic intent. The acquisition of complete risk factor information and important clinical follow-up data (specifically the occurrence of breast and non-breast cancer in these high-risk individuals) is underway via medical record review and patient/next of kin follow-up questionnaire. In this initial phase, prior to complete documentation with outside records, 14 potential cases of breast cancer following prophylactic mastectomy have been identified.

The laboratory investigators have developed appropriate screening methods for the ascertainment of BRCA1 mutations and several mutations have been identified. We have also developed techniques for the analysis of small breast lesions found in archival paraffin-embedded specimens, including atypia and lobular carcinoma in situ.

Anatomical Samples, High-Risk, Genetic Alterations, Prophylactic Mastectomy, Breast Cancer

Unclassified

Unclassified

Unclassified

Unlimited
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

( ) Where copyrighted material is quoted, permission has been obtained to use such material.

( ) Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

( ) Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

( ) In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

( ) For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 32 CFR 219 and 45 CFR 46.

( ) In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

______________________________  __________________________
Principal Investigator's Signature  Date  8/16/95

<table>
<thead>
<tr>
<th>Accession For</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NTIS</td>
<td>CRA&amp;I X</td>
</tr>
<tr>
<td>DTIC</td>
<td>TAB</td>
</tr>
<tr>
<td>Unannounced</td>
<td></td>
</tr>
<tr>
<td>Justification</td>
<td></td>
</tr>
</tbody>
</table>

By ____________________________
Distribution /

<table>
<thead>
<tr>
<th>Availability Codes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dist</td>
<td>Avail and/or Special</td>
</tr>
<tr>
<td>A-1</td>
<td></td>
</tr>
</tbody>
</table>
ANNUAL REPORT: INTRODUCTION

Breast Cancer: Options for Prevention - Medical

At the present time, options for breast cancer prevention are limited (1). Possible medical approaches include some manipulation of endocrine function, such as long-term use of tamoxifen or a contraceptive combination including a gonadotropin-releasing hormone agonist, low-dose estrogen and an intermittent progestogen (1). These approaches have major lifestyle implications, possible morbidities upon long-term application, and no proof of efficacy. The role of tamoxifen as a possible breast cancer preventive measure is currently the subject of a placebo-controlled trial. However, within the scientific community, there exists uncertainty regarding its possible net benefit (2,3). Moreover, recent additional data regarding tamoxifen's link with endometrial cancer have prompted recontacting all participants to inform them of its risks and the need for more aggressive follow-up for endometrial cancer (4). Early detection via an aggressive screening approach (or secondary prevention) is another option, utilizing the early initiation of mammography and regular breast self examinations and clinical breast examinations (5). However, no data exist to demonstrate the efficacy of this strategy in improving detection or reducing mortality for breast cancer (6). Moreover, the increased density of breasts of younger women may limit the sensitivity and specificity of mammography in this population (7,8). Some have quoted a false-negative rate with mammography in premenopausal woman as high as 40% (9). Thus, for individuals at substantial risk for breast cancer, no currently available medical approach to prevention is considered reliable and efficacious.

Breast Cancer: Options for Prevention - Surgical

Removal of the tissue at risk, namely prophylactic mastectomy (PM) represents an option for women at significantly increased risk of breast cancer. An extreme approach, prophylactic surgery currently is considered our most effective preventive maneuver, although its efficacy has not been systemically studied (see below).

At many centers, the most commonly performed PM is a subcutaneous mastectomy (SCM) (10). This procedure removes approximately 95% of breast glandular tissue but preserves the nipple-areolar complex, thus providing a more aesthetic result without the need for additional nipple reconstructive surgery (11-13). However, because some glandular breast tissue remains beneath the nipple, the procedure has been challenged as a prophylactic maneuver. In fact, in one rodent model of mammary carcinogenesis, prophylactic subcutaneous mastectomy failed to demonstrate a proportionate reduction in mammary cancer risk (14). In the medical literature, scattered reports exist of breast cancer developing in women after prophylactic subcutaneous mastectomy (15,16).

Because of concerns of incomplete protection with SCM, some practitioners recommend total mastectomy (TM), namely removal of the entire breast including the nipple-areolar complex, as the preferred prophylactic procedure (15). It should be noted, however, that controversy exists whether any mastectomy can be truly
prophylactic (17,18). In fact, even following total mastectomy or modified radical mastectomy, careful pathologic studies consistently identify residual breast tissue in the anterior chest wall or axillary tail (10,19).

Despite the utilization of PM for women at increased risk of breast cancer, we have incomplete data regarding its efficacy. Long-term rigorous, systemic follow-up of a large and uniformly treated population has not been done (17). Data regarding quality of life, complications, the need for repeat breast surgeries, and the occurrence of breast and non-breast cancers in these women are also lacking (9). Moreover, there has been inadequate definition of the underlying risk of the various populations undergoing this procedure.

Genetic Susceptibility Testing: An Immediate Challenge

The identification within the past year of the first major human susceptibility gene for breast cancer, BRCA1, (20), the localization of additional breast cancer susceptibility genes, e.g. BRCA2 (21) along with the rapid development and marketing of commercially available genetic testing raises several concerns (22). At present, the medical community's diagnostic capabilities exceed our prevention offerings for high-risk women. For such time as prophylactic mastectomy is considered the most efficacious approach for these individuals, we must be able to provide patients and providers with appropriate follow-up information regarding the procedure's efficacy and side effects. As was recently stated by the American Society of Human Genetics:

Women in high-risk families should be informed about the risks, benefits, and limitations of predictive testing and about the uncertainty about the effectiveness of current monitoring and prophylactic interventions . . . . As yet, no proved methods of primary prevention for breast or ovarian cancer exist. Prophylactic mastectomy or oophorectomy may be effective, but the results of systematic long-term follow-up to determine the frequency of cancer in residual tissue or in other organs are not available. Research to evaluate the efficacy and risks of monitoring and prevention strategies is essential to determine if genetic testing translates into reduction of morbidity and mortality for breast and ovarian cancer and to determine if specific management approaches have adverse outcomes (23)

This point was also emphasized in a recent JAMA review:

Advances in molecular genetics have provided data that allow risk estimation for women with inherited mutations in dominant cancer susceptibility genes. Unfortunately, studies that allow estimation of risk reduction from prophylactic surgical intervention are essentially unavailable, and the science of chemoprevention is in its infancy. Furthermore, there are limited data available to assess the efficacy of enhanced surveillance programs for individuals at high risk for developing breast cancer (24).
Purpose of Present Work

The purpose of the present work is to determine the clinical outcome of a large population of women who had prophylactic mastectomy at the Mayo Clinic for increased risk of breast cancer; we will also determine outcome in BRCA1 carriers.

General Methods of Approach

We recognize the heterogeneity of our large patient population electing prophylactic mastectomy over a period of almost 25 years (1966 thru 1987). Our general approach to the problem is twofold: First, we will determine the expected risk of the individuals undergoing this procedure and second, we will determine their actual outcome. To determine the expected risk, a baseline breast cancer risk assessment, based on factors pertinent at the time of prophylactic mastectomy, will be calculated for each patient. This risk will be based on family history information, history of benign breast disease, and reproductive factors (see Appendix I). Given the identification of BRCA1 within the last year, we will also identify BRCA1 carriers from those individuals with appropriate family histories. The expected likelihood of breast cancer in BRCA1 carriers has been reported to approach 85 percent over a woman's lifetime (25,26).

To determine the actual outcome of these individuals, we are utilizing a thorough review of the medical record, as well as a detailed follow-up patient questionnaire that will be mailed to all living individuals and a similar questionnaire mailed to next of kin if the prophylactic mastectomy patient is known to be deceased. The outcome information will include cancer occurrences - breast, ovary, colon, or other; post-prophylactic mastectomy surgical morbidities and various measures of psychosocial satisfaction (seeking sources of funding for the latter studies) (Appendix I).

ANNUAL REPORT: BODY

Experimental Methods - Clinical

Chart Review: To date, we have reviewed the charts on 782 individuals listed in the Mayo Data Base as having had prophylactic mastectomy. Of these, 61 have been excluded from further participation because of the following reasons: Having had prior history of breast cancer - 15; breast cancer suspected and confirmed at time of surgery - 44; cosmetic surgery only - 2. Thus, out of this initial group of 782 patients listed in our surgical records as having had prophylactic mastectomy, a total of 721 (92.2%) have been found at official chart review to, in fact, have had a prophylactic mastectomy. During this chart review, information about vital status, breast surgeries, breast cancer subsequent to prophylactic mastectomy, other cancers, and various risk factors for breast cancer have been abstracted from the patient record (see Appendix II).

Follow-up Questionnaire: Appropriate follow-up questionnaires were developed for each possible category of patient electing prophylactic mastectomy (see
Appendix III). Following completion of chart review, the appropriate set of follow-up questionnaires is sent to the patient or next of kin (if patient deceased). Thus far, a total of 408 questionnaires have been sent; the first mailings were sent on June 27, 1995. Thus far, 203 individuals have returned completed forms. Seven individuals indicated that they did not want to participate. The other forms are outstanding as of July 31, 1995. Second mailings will be sent to follow the unanswered questionnaires. Telephone follow-up will be utilized as needed.

Clinical Outcomes: Breast Cancer: As of 7-31-95, based on the nurse abstractor's review of the patient charts, a total of 14 possible cases of breast cancer following prophylactic mastectomy have been identified. These are preliminary data as we await necessary documentation and physician review of these cases.

Experimental Methods - Laboratory

Histopathologic Review: We have developed a system for the acquisition of tissue blocks and slides for all cases confirmed by chart review to represent prophylactic mastectomy. These will be reviewed and characterized by Dr. T. Crotty, Surgical Pathology.

BRCA1 Mutation Detection: During the first year of the project, we have been developing methods for the detection of mutations in the BRCA 1 gene in our prophylactic mastectomy cohort. Such methods will need to ascertain accurately the BRCA1 carriers in this cohort, so as to assess the preventive capability of prophylactic mastectomy in this highest risk group. Our strategy is to develop technically simple, sensitive, and specific screening assays for as many of the currently known BRCA1 mutations (20,27-32) as possible.

Our first screening method involves the use of restriction endonucleases. Some known BRCA 1 mutations either create a new restriction enzyme site or remove an existing site; both situations can be distinguished easily from wildtype DNA on appropriate agarose gels. In some situations the mutation does not create or delete a site; we then induce an artificial site by the use of a PCR primer with a predesigned mismatch (AIRS=Artificial Induction of Restriction Sites) (33-40). A second screening method is to PCR amplify an exon of interest and then to electrophorese the resulting product on a gel of high agarose content. An insertion or a deletion of greater than three base pairs is unambiguously detected by this assay.

Many known (and most unknown) BRCA 1 mutations, cannot be detected by these initial screening methods. To ascertain additional mutations, we are using single stranded conformational polymorphism (SSCP) analysis (31). Although this assay will only detect mutations that alter the secondary structure of individual DNA strands, it has the advantage of detecting new, unpublished mutations. The final mutation screening assay we are using is the Protein Truncation Test (PTT) (41-43). It involves amplifying genomic DNA with a modified PCR primer and then evaluating that product in a coupled transcription/translation reaction. Nonsense or frameshift mutations which result in a truncated protein are detected as novel discrete bands on a SDS-polyacrylamide gel. This assay is useful for screening
exon 11 of the BRCA1 gene, which encodes 61 percent of the gene. Nonsense and frameshift mutations are common in this exon (27-32). Table 1 compiles the published (20, 27-31) and unpublished (32) BRCA1 mutations to date and lists the assays we will use to screen for these mutations.

Our strategy is to apply these screening assays to all patients in our prophylactic mastectomy cohort with a family history of breast cancer. To determine the specificity of our screening methods, we will evaluate all potentially positive specimens by DNA-sequencing. To evaluate the sensitivity of our screening methods, we will also evaluate multiple negative specimens by DNA-sequencing. In the course of these studies we may find that it may be necessary to DNA-sequence some exons from the start if our screening methods are not very accurate.

We have isolated DNA from 10 patients who have a positive breast/ovarian cancer family history and have begun to evaluate them using the above BRCA mutation screening and DNA-sequencing strategy.

Using SSCP, agarose gel, and AIRS, we detected a germline exon 16 mutation in one patient. DNA-sequencing revealed a mutation similar to the published 5085 del 19 → ter 1671 mutation; our patient’s mutation was 5083 del 19 → ter 1671. This mutation clearly disrupts the reading frame of the BRCA1 mRNA and very likely results in a nonfunctional protein. In addition, we have also found a second germline exon 15 mutation (4719 Glucose → A, Val 1534Met) in this patient. This missense mutation may very well be a normal DNA polymorphism and we are evaluating a control population to test this hypothesis. In a second patient, we also observed an unpublished exon 5 mutation. This mutation, 310 G → A, Cys64Tyr, removes the last cysteine of the zinc finger DNA-binding motif of BRCA1. Other mutations in this cysteine and in other cysteines of this motif have been previously reported to be linked with breast cancer in some BRCA families (31). Thus, it is very likely that the germline mutation we observed is causative in this patient. All of the above mutations were verified by sequencing the DNA in both directions. Through SSCP we recently discovered what could be either a DNA-polymerorphism or a novel mutation in exon 9 in 4 of these 10 patients. We are currently DNA-sequencing these 4 specimens to define the underlying sequence alteration. We are also testing a control population to determine if the alteration is a polymorphism or a new mutation.

Analysis of Concomitant Benign Breast Tissue and Lobular Carcinoma in Situ (LCIS):
One of the strengths of this work is the opportunity to examine matching benign breast tissue from the contralateral breast (removed prophylactically) in women who have breast cancer specimens at Mayo (removed via radical/modified radical mastectomy). In addition, LCIS specimens can be compared with benign specimens from the same patient. These analyses require the development of inexpensive and practical techniques for isolating DNA from small paraffin-embedded breast lesions. To this end, we developed an inexpensive and reproducible DNA isolation technique using paraffin-embedded tissue sections mounted on cellulose acetate sheets. Regions of interest can be removed from the sheet using a scalpel. This simple technique greatly improved the yield of selected
cell populations (> 84 percent), thereby decreasing contamination by surrounding normal tissue DNA. This is a significant contribution since ≥ 20 percent normal cells can mask loss of heterozygosity (LOH). For example, Figure 1 exemplifies the small areas of atypical cells used for DNA amplification.

DNA isolated from paraffin-embedded tissue is often fragmented and very small, therefore all PCR parameters, especially template denaturation, primer annealing and extension times were optimized. In our experience, only 20 percent of microsatellite markers are efficacious on paraffin DNA. Extensive testing of primer pairs was required for optimal DNA allelotype resolution. See Figure 2 for examples of PCR allele patterns. Compared with previously published reports using paraffin-DNA, our banding results are excellent. Improved band resolution allows more accurate LOH determination.

Initially, 16 breast cancer specimens were evaluated by this new technique. Normal breast DNA was isolated from corresponding contralateral prophylactic mastectomy tissue. As depicted in Figure 3, the regions and frequency of LOH on chromosome 17 were comparable to previously reported data using fresh frozen breast cancer DNA. However, there was an unacceptably high indeterminate rate secondary to the small amounts of normal control ductal tissue available in breast specimens from observation from older women. Subsequently, normal control lymph node DNA and breast cancer DNA from each patient yielded a significant decrease in indeterminate DNA patterns. To ensure that breast cancer cells were not present in the lymph node tissue utilized for DNA isolation, immunohistochemical techniques with anticytokeratin antibodies were employed.

We next used these optimized conditions to isolate very small areas of premalignant/malignant changes in human breast tissue. The new microdissection technique could isolate approximately 20 to 100 cells. The DNA isolated from such a small number of cells was successfully amplified by our PCR conditions. Recently, we evaluated 18 specimens of atypical ductal hyperplasia, LCIS and ductal carcinoma in situ (DCIS) for LOH in the regions of BRCA1 and BRCA2. Our results showed 15 percent LOH for the BRCA2 region in LCIS specimens and approximately 10 percent LOH for the BRCA1 region in DCIS specimens. Figure 4 illustrates an example of LOH for these small lesions. Of interest, the areas of genetic loss are extremely small, emphasizing the need for optimal techniques for evaluation of early breast lesions.

CONCLUSIONS:

The primary question posed in this work, namely the efficacy of prophylactic mastectomy in women at high risk for breast cancer, is even more timely today than when this grant was first submitted. The identification of breast cancer susceptibility genes and the rapid development of commercially available testing for carriers of mutations in these genes will soon permit more precise risk assessment from many women from breast cancer families. Until alternative preventive measures for breast cancer are available, it is imperative that the medical community have complete follow-up information regarding prophylactic mastectomy to be able to present this option realistically to individual women. To
inform a woman that she is a carrier of a breast cancer predisposing gene, and thus at very high risk for breast cancer, and to tell her that prophylactic mastectomy is an option but that we lack follow-up data regarding its efficacy or side effects, is unacceptable. Besides studying the clinical outcomes of women who have had prophylactic mastectomy (i.e. cancer occurrences and post-surgical morbidities), we are also asking women to comment on various psychosocial measures following prophylactic mastectomy. This information is being collected, and we are attempting to find funding for the appropriate analyses of these psychosocial data.

During this first year of the grant award, we have demonstrated the following:

1. Accuracy of the Mayo Clinic's surgical listing of prophylactic mastectomy. Of the 782 charts abstracted thus far, 92.2 percent have indeed been confirmed to have had prophylactic mastectomy.

2. Feasibility of combined chart review and patient/next of kin questionnaire to obtain complete risk factor information and clinical follow-up data

3. Establishment of satisfactory mechanisms for obtaining and review of histopathologic material

4. Ability to detect BRCA1 germ line mutations in very high risk individuals

5) Ability to isolate DNA from small paraffin-embedded specimens of benign breast lesions, and LCIS for comparative genetic analyses.

Thus, we are on schedule to complete the scope of the work described in our grant, DAMD 17-94-J-4216.
REFERENCES:


## Table 1: Mutation Screening Assays for Known BRCA1 Mutations

<table>
<thead>
<tr>
<th>Exon</th>
<th>Codon Mutation</th>
<th>Base Mutation &amp; Terminal Codon if Applicable</th>
<th>Mutation Screening Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ex. 2</td>
<td>23del AG</td>
<td>185 del AG-&gt;ter39</td>
<td>SSCP, AIRS</td>
</tr>
<tr>
<td>Ex. 2</td>
<td>24del 11</td>
<td>188 del 11-&gt;ter39</td>
<td>SSCP, Agarose</td>
</tr>
<tr>
<td>Ex. 5</td>
<td>Cys 61 Gly</td>
<td>300 T -&gt; G</td>
<td>SSCP, NRS</td>
</tr>
<tr>
<td>Ex. 5</td>
<td>Cys 64 Gly</td>
<td>309 T -&gt; G</td>
<td>SSCP</td>
</tr>
<tr>
<td>In. 5</td>
<td>T -&gt; G ins59</td>
<td>331 + 27-&gt; C</td>
<td>NA</td>
</tr>
<tr>
<td>Ex. 8</td>
<td>Glu 169 ter</td>
<td>624 C -&gt; T</td>
<td>SSCP, AIRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>266del TT</td>
<td>916 del TT-&gt;ter 285</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>270 ins 11</td>
<td>326 ins 11-&gt;ter 301</td>
<td>PTT, Agarose</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>333 ins A</td>
<td>1128 ins A-&gt;ter 345</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>351del 11</td>
<td>1201 del 11-&gt;ter 361</td>
<td>PTT, Agarose, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>392del 40</td>
<td>1254 del 40-&gt;ter 398</td>
<td>PTT, Agarose</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>407 ins C</td>
<td>1339 ins C</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Glu 526 ter</td>
<td>1695 C -&gt; T</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Glu 582 ter</td>
<td>1806 C -&gt; T</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Leu 599 ter</td>
<td>2035 T -&gt; A</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>654 del A</td>
<td>2073 del A</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>655 ins A</td>
<td>2080 ins A-&gt;ter 672</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>720 ins A</td>
<td>2278 ins A</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>725 del G</td>
<td>2294 del G-&gt;ter 735</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>765del AG</td>
<td>2415 del AG-&gt;ter 768</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Thr826Lys</td>
<td>2596 C -&gt; A</td>
<td>??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>826 del C</td>
<td>2477 del C-&gt;ter 845</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>894 del A</td>
<td>2800 del A-&gt;ter 901</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Glu 908 ter</td>
<td>2841 G -&gt; C</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>915 del TC</td>
<td>2853 del TC-&gt;ter 915</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>956 del 5</td>
<td>2982 del 5-&gt;ter 968</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1002 del A</td>
<td>3121 del A-&gt;ter1023</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1016 ins A</td>
<td>3166 ins 5-&gt;ter 1026</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1160 del 11</td>
<td>3598 del 11-&gt;ter 1166</td>
<td>PTT, Agarose, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Leu 1081 ter</td>
<td>3388 T -&gt; A</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1111 del 4</td>
<td>3450 del 4-&gt;ter 1085</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Arg 1203 ter</td>
<td>3726 C -&gt; T</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1234 del A</td>
<td>3821 del A-&gt;ter 1242?</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Glu 1250 ter</td>
<td>3867 G -&gt; T</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1252del 4</td>
<td>3875 del 4-&gt;ter 1262</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1259del T</td>
<td>3866 del T-&gt;ter1263</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1290del AA</td>
<td>3986 del AA-&gt;ter 1293</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Glu 1313 ter</td>
<td>4056 C-&gt;T</td>
<td>PTT, NRS??</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>1355 del 4</td>
<td>4184 del 4-&gt;ter 1364</td>
<td>PTT</td>
</tr>
<tr>
<td>Ex. 11</td>
<td>Glu 1395 Glu</td>
<td>4304 G -&gt; A</td>
<td>??</td>
</tr>
<tr>
<td>Ex. 13</td>
<td>Arg 1443 Gly</td>
<td>4448 C -&gt; G</td>
<td>SSCP</td>
</tr>
<tr>
<td>Ex. 13</td>
<td>Arg 1443 ter</td>
<td>4448 C-&gt; T</td>
<td>SSCP</td>
</tr>
<tr>
<td>In. 13</td>
<td>4476 + 6T -&gt; C</td>
<td>4476 + 6T C</td>
<td>Agarose??</td>
</tr>
<tr>
<td>Ex. 15</td>
<td>Glu 1541 ter</td>
<td>4740 G -&gt; T</td>
<td>SSCP, NRS</td>
</tr>
<tr>
<td>Ex. 16</td>
<td>Tyr 1563 ter</td>
<td>4808 C -&gt; G</td>
<td>SSCP, AIRS??</td>
</tr>
<tr>
<td>Ex. 16</td>
<td>Pro 1637 Leu</td>
<td>5029 C -&gt; T</td>
<td>SSCP, NRS</td>
</tr>
<tr>
<td>Ex. 16</td>
<td>1656del 19</td>
<td>5085 del 19-&gt;ter 1671</td>
<td>SSCP, Agarose</td>
</tr>
<tr>
<td>Ex. 18</td>
<td>Ala 1708 Glu</td>
<td>5242 C -&gt; A</td>
<td>SSCP, AIRS</td>
</tr>
<tr>
<td>In. 18</td>
<td>del A-&gt;del exon 19-&gt;ter 1732</td>
<td></td>
<td>??</td>
</tr>
<tr>
<td>In. 18</td>
<td>5271 + 1G -&gt; T</td>
<td>5271 + 1G -&gt; T</td>
<td>??</td>
</tr>
<tr>
<td>Ex. 19</td>
<td>Lys 1727 ter</td>
<td>5288 A -&gt; T</td>
<td>SSCP</td>
</tr>
<tr>
<td>In. 19</td>
<td>5312 + 2del T</td>
<td>5312 + 2del T</td>
<td>??</td>
</tr>
<tr>
<td>Ex. 20</td>
<td>1768 ins C</td>
<td>5382 ins C-&gt;ter 1829</td>
<td>SSCP</td>
</tr>
<tr>
<td>Ex. 21</td>
<td>1773 ins C</td>
<td>5438 ins C-&gt;ter 1829</td>
<td>SSCP, NRS</td>
</tr>
<tr>
<td>Ex. 21</td>
<td>Met 1775 Arg</td>
<td>5443 T -&gt; G</td>
<td>SSCP, AIRS</td>
</tr>
<tr>
<td>Ex. 24</td>
<td>Arg 1835 ter</td>
<td>5622 C -&gt; T</td>
<td>SSCP, AIRS??</td>
</tr>
<tr>
<td>Ex. 24</td>
<td>1837del G</td>
<td>5629 del G</td>
<td>SSCP</td>
</tr>
<tr>
<td>Ex. 24</td>
<td>1853 ins A</td>
<td>5677 ins A-&gt;ter 1853</td>
<td>SSCP, AIRS</td>
</tr>
</tbody>
</table>

Agarose = PCR amplification followed by agarose gel electrophoresis
AIRS = Artificial Induction of Restriction Site
NRS = Natural Restriction Site
PTT = Protein Truncation Test
SSCP = Single Stranded Conformation Polymorphism
?? = Test still being developed
Figure 1: Circled area illustrates a region of atypia used for DNA amplification.

Loss of Heterozygosity in Human Breast Tumors

Figure 2: Microsatellite evaluation of LOH in the BRCA1 region. Specimens from two women with breast cancer are illustrated. L=lymph node DNA; N=normal breast duct DNA; A=atypical duct DNA; T=breast cancer DNA. Concentrations of each DNA sample were adjusted to give comparable band intensity for LOH determination. Figure on left represents LOH in tumor tissue with loss of upper band intensity.

Figure 3: An Allelotype of chromosome 17 showing frequency and location of genetic losses in paraffin-embedded breast cancer DNA.

Marker: D13S290

Marker: D17S807

Figure 4: Microsatellite evaluation of LOH in the BRCA2 region. Specimens from three women with atypia are illustrated. Normal breast duct DNA; atypical (carcinoma in situ) ductal DNA. Notice loss of bands in atypia lane representing LOH.
Mayo Clinic
200 First Street Southwest Rochester, Minnesota 55905 Telephone 507 284-2511

You had a prophylactic mastectomy (preventive removal of the breast) performed by Mayo Clinic's plastic surgeons. Dr. John E. Woods and Dr. P. G. Arnold from the Department of Surgery at Mayo and I would like to ask you for some information.

Our primary purpose in contacting you at this time is to assess your particular reasons for having had a prophylactic mastectomy and to ask how your health has been following that surgery. In this packet, you will find a form containing questions about your family history of breast cancer, as well as your menstrual and reproductive history. We will also ask about any breast problems that you may have had since your prophylactic mastectomy, including the possibility of any breast cancer or the need for any additional breast surgery. We will also ask you whether you have developed any other cancers.

This follow-up work that we are now doing is part of an approved Mayo Clinic study. We hope that the follow-up information learned through this study will help physicians counsel women in the future as they think about having a prophylactic mastectomy performed. As with your other Mayo Clinic records, the information that you provide us will be kept strictly confidential.

We would like to emphasize that the reason for asking these questions is not that we are concerned about silicone implants causing cancer. Most women who had prophylactic mastectomy at Mayo did so because of a concern about breast cancer. These concerns were based on a variety of reasons, including pre-cancerous change in the breast, a history of breast cancer in the family, or having had multiple prior biopsies for suspicious lumps in the past. These factors are known to increase a woman's risk of a breast cancer to some extent. Some of these factors have also been associated with the development of other types of cancer, such as ovarian cancer or colon cancer. Thus, it is important that we learn of any breast or non-breast cancer problem that you may have had.

We would like to address the concerns that have been raised in the press about silicone implants and their possible health hazards, including links with breast cancer and several arthritis-like conditions (also called connective tissue diseases). We would like to update you regarding the status of well-controlled medical studies of patients who have had silicone implants. A recently completed Mayo Clinic study looked at the
development of arthritis-like illnesses in Rochester-area women who had silicone-containing implants. Mayo investigators saw no evidence for a link between these implants and any connective tissue disease. These results have been published recently in The New England Journal of Medicine. Moreover, a Canadian group recently studied women who had breast augmentation (or enlargement), with implant placement, for any evidence of later increased breast cancer risk. In fact, these investigators saw fewer breast cancers in women who had implants compared with women in the general population (N Engl J Med, Berkel et al, June 18, 1992). This finding by no means indicates that implants lower risk, but we have no reason to think that they contribute to breast cancer.

We appreciate your help in this study and hope that you are willing to provide the information. If you do not wish to complete the questionnaire, please indicate this below and return this letter since it will make a follow-up call unnecessary. Please understand that current or future medical care at the Mayo Clinic for you and your family members will not be affected by your decision. Specifically, your care will not be jeopardized if you choose not to complete the questionnaire.

If you have family members with breast cancer, and indicate so on the enclosed form, we will be contacting you again for more detailed family information.

We thank you for your consideration.

Sincerely yours,

Lynn C. Hartmann, M.D.
Mayo Women’s Cancer Program

John E. Woods, M.D.
Department of Surgery

Phillip G. Arnold, M.D.
Department of Surgery

☐ I do not wish to participate further in this survey.

KPOO
PROPHYLACTIC MASTECTOMY
FOLLOW-UP STUDY

SURVEY RESEARCH CENTER
Please enter above any missing information or change any that is incorrect.

Instructions: Please check the appropriate box or fill in the blank as indicated.

Today's Date \( \underline{\underline{\underline{}}} / \underline{\underline{\underline{}}} / \underline{\underline{\underline{}}} \)

Month Day Year

**MEDICAL HISTORY**

**WE ARE INTERESTED IN THE MEDICAL HISTORY AND FAMILY HISTORY OF WOMEN WHO HAVE CHOSEN TO HAVE A PROPHYLACTIC MASTECTOMY.**

1. At what age did you begin menstruating?
   \[ \underline{\underline{\underline{}}} \text{ years} \]

2. Have you had children?
   1. [ ] No
   2. [ ] Yes

   How old were you when your first child was born?
   \[ \underline{\underline{\underline{}}} \text{ years} \]

3. Did you have any breast biopsies before your prophylactic mastectomy?
   1. [ ] No
   2. [ ] Yes

   How many breast biopsies did you have before your prophylactic mastectomy?
   \[ \underline{\underline{\underline{}}} \text{ Number of breast biopsies} \]

   Did any of the biopsy results show worrisome findings?
   1. [ ] No
   2. [ ] Yes

4. Has your (blood-related) mother had breast cancer?
   1. [ ] No
   2. [ ] Yes
   3. [ ] Don’t know

   If yes, in what year?
   \[ \underline{\underline{\underline{}}} \]

   What is her year of birth?
   \[ \underline{\underline{\underline{}}} \]

Page 1
5. Do you have any blood-related sisters?

1 □ No 2 □ Yes

If yes, how many? ________

Have any of your sisters had breast cancer?
(Do not include yourself in responding to this question.)

1 □ No 2 □ Yes

SISTER #1
If yes, in what year? ________
What is her year of birth? ________

SISTER #2
In what year? ________
What is her year of birth? ________

SISTER #3
In what year? ________
What is her year of birth? ________

SISTER #4
In what year? ________
What is her year of birth? ________

SISTER #5
In what year? ________
What is her year of birth? ________
6. Do you have any blood-related daughters?

1 □ No 2 □ Yes

If yes, how many? __________

Have any of your daughters had breast cancer?

1 □ No 2 □ Yes

DAUGHTER #1
If yes, in what year? __________
What is her year of birth? __________

DAUGHTER #2
In what year? __________
What is her year of birth? __________

DAUGHTER #3
In what year? __________
What is her year of birth? __________

DAUGHTER #4
In what year? __________
What is her year of birth? __________

DAUGHTER #5
In what year? __________
What is her year of birth? __________

7. Have other blood relatives of yours, including men in the family, had breast cancer?

1 □ No 2 □ Yes

If yes, please list relative: __________________________________________
__________________________________________________________________
__________________________________________________________________

8. Have any of your blood relatives had ovarian cancer?

1 □ No 2 □ Yes
9. Have you ever been diagnosed with breast cancer?
   1 □ No  2 □ Yes

   If yes, in what year? __________ year
   In which breast? 1 □ Right  2 □ Left
   What treatment did you have? __________________________

   Did your breast cancer ever spread?
   1 □ No  2 □ Yes

   If yes, where?
   __________________________

   In what year was this discovered?
   __________ year
   What treatment did you have?
   __________________________

10. Have you had any other cancers?

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>No</th>
<th>Yes</th>
<th>What year was cancer found?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
<tr>
<td>Colon cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
<tr>
<td>Uterine cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
</tbody>
</table>

Other cancer(s) (please list)
______________________________
______________________________
______________________________
______________________________
17. Overall, how satisfied are you with your prophylactic mastectomy(ies)?

1 □ Very satisfied  2 □ Satisfied  3 □ Neither  4 □ Dissatisfied  5 □ Very dissatisfied

Please explain your reasons for your answer to this question.

__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________

18. Knowing what you do now, would you choose to have prophylactic mastectomy(ies) if you had it to do over again?

1 □ Definitely would  2 □ Probably would  3 □ Unsure  4 □ Probably would not  5 □ Definitely would not

Please explain your reasons for your answer to this question.

__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________

19. Knowing what you do now, would you choose to have breast reconstruction after prophylactic mastectomy(ies) if you had it to do again?

1 □ Definitely would  2 □ Probably would  3 □ Unsure  4 □ Probably would not  5 □ Definitely would not

Please explain your reasons for your answer to this question.

__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________
<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Mayo</td>
</tr>
<tr>
<td>SSN</td>
<td></td>
</tr>
<tr>
<td>Address</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td></td>
</tr>
<tr>
<td>State</td>
<td></td>
</tr>
<tr>
<td>Zip Code</td>
<td></td>
</tr>
<tr>
<td>Plus Four</td>
<td></td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
</tr>
<tr>
<td>Spouse</td>
<td></td>
</tr>
<tr>
<td>Other names</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>C=Caucasian</td>
</tr>
<tr>
<td></td>
<td>B=Black</td>
</tr>
<tr>
<td></td>
<td>AI=Am.Indian</td>
</tr>
<tr>
<td></td>
<td>AN=Alaska Native</td>
</tr>
<tr>
<td></td>
<td>AS=Asian</td>
</tr>
<tr>
<td></td>
<td>H=Hispanic</td>
</tr>
<tr>
<td></td>
<td>PI=Pacific Islander</td>
</tr>
<tr>
<td></td>
<td>O=Other, spec</td>
</tr>
<tr>
<td></td>
<td>U=Unknown</td>
</tr>
<tr>
<td>Status</td>
<td>A=Alive</td>
</tr>
<tr>
<td></td>
<td>D=Dead</td>
</tr>
<tr>
<td></td>
<td>Death Indicator</td>
</tr>
<tr>
<td></td>
<td>Y=Dead</td>
</tr>
<tr>
<td></td>
<td>N=Alive</td>
</tr>
<tr>
<td>Date of Birth</td>
<td></td>
</tr>
<tr>
<td>Age at PM</td>
<td></td>
</tr>
<tr>
<td>Date of Death</td>
<td></td>
</tr>
<tr>
<td>Date of last follow-up</td>
<td></td>
</tr>
<tr>
<td>EXCLUDE (0-4, ?=code window)</td>
<td></td>
</tr>
<tr>
<td>Date abstracted</td>
<td></td>
</tr>
<tr>
<td>Abstractor</td>
<td>JLJ, RSM</td>
</tr>
</tbody>
</table>

For Study 15942:
- Mayo breast surgery
- Family hx cancer
- Tissue tracking
BREAST CANCER PRIOR TO PROPHYLACTIC MASTECTOMY DIAGNOSED ELSEWHERE

_ Breast Cancer prior to PM diagnosed outside of Mayo (y=yes n=no)
_ Date of breast ca dx EW
_ Side of breast cancer (r/l)
_ Path reports available (y=yes n=no)
_ Date read at Mayo
_ Cancer pathology from EW/lab sheets (use cancer codes S1594201)

BREAST CANCER SUBSEQUENT TO PM on PM Side (Mayo or other inst.)

_ Breast cancer following PM (y=yes n=no)
_ Institution* Date of breast cancer Side Site*
_ Path rep't available (y=yes n=no)
_ Date read at Mayo
_ Cancer pathology from EW/lab sheets (use cancer codes S1594201)
_ Institution* Date of breast cancer Side Site**
_ Path rep't available (y=yes n=no)
_ Date read at Mayo
_ Cancer pathology from EW/lab sheets (use cancer codes S1594201)

*Institution: (M=Mayo S=Scottsdale J=Jacksonville EW=Elsewhere)
**Site: 1=Residual breast tissue 2=Chest wall 3=Axillary node 4=Supraclavicular node 5=???
OTHER PRIMARY CANCERS
- Other Primary cancers (y=yes n=no)
  1=Ovarian  2=Colon  3=Uterine  0=Other, specify
  Date of other cancer
- Second other primary cancer (code above)
  Date of other cancer

BENIGN BREAST BIOPSIES ELSEWHERE
- Total number of BBB elsewhere prior to Prophylactic Mastectomy
  (enter 99 multiple biopsies, but number unknown)
MAMMOGRAMS
- Mammogram before PM at Mayo (y/n)
  Date closest to PM
- Number of mammograms at Mayo (10 year window prior to PM)
- Mammogram from elsewhere, read at Mayo
  Date read at Mayo

GENETIC REVIEW
- Genetics Review (y/n)
  Date of Genetics Review
**RISK FACTORS AT TIME OF PM (enter one field only) (.u if unknown)**

- Age at menarche
- Age at birth of first child
- Menopause 1=Pre-menopause  2=Post-menopause (.u=unknown)
- Age at Menopause
- IF Post-Menopausal 1=Natural  2=Artificial  3=Hormone Replacement Therapy  .u=unknown
  - Cessation of menses 1=Hyst, no ooph  2=Hyst, unilat ooph  3=TAH/BSO  4=Bilat. ooph  5=Hyst. no info on ooph  6=Post chemo  7=Post radiation
- Height in cm
- Weight in kg
- Gravidity
- Questions/Review MD
- Questions for RN

**Comments**
DEATH CERTIFICATE INFORMATION

- Death Certificate available* (Y=yes N=no R=requested)  
  Date requested

* Death Certificate not available from:
  Alabama, Idaho, Indiana, New Jersey,
  New York, North Dakota, and Ontario,
  Canada

- Breast cancer noted on Death Certificate (Y=yes N=no)
  if yes, 1=Immediate cause 2=Consequence of .u=Unknown

- Other cancers noted on Death Certificate
  if yes, 1=Ovarian 2=Colon 3=Uterine .o=other, specify
Follow-up Screens

Date to Follow-up (Survey Research Center)
No Contact (X = no contact)
Date Follow Up Complete

Comments
Our records indicate that you are the next of kin of Ms. 8~, who had a prophylactic mastectomy (preventive removal of the breast) performed by Mayo Clinic's plastic surgeons. We understand that Ms. 9~ is deceased. Dr. John E. Woods and Dr. P. G. Arnold from the Department of Surgery at Mayo and I would like to extend our sympathy to you and would also like to ask you for some information.

Our primary purpose in contacting you at this time is to clarify Ms. 9~’s reasons for having had a prophylactic mastectomy and to ask a few health-related questions pertaining to her life after her prophylactic mastectomy. In this packet, you will find a form containing questions about her family history of breast cancer and her menstrual and reproductive history. We will also ask about any breast problems that she may have had following her prophylactic mastectomy, including the possibility of any breast cancer or the need for additional breast surgery. We will also ask whether she developed any other cancers.

This follow-up work that we are now doing is part of an approved Mayo Clinic study. We hope that the follow-up information learned through this study will help physicians counsel women in the future as they think about having a prophylactic mastectomy performed. As with Ms. 9~’s other Mayo Clinic records, the information that you provide us will be kept strictly confidential.

If Ms. 9~ had family members with breast cancer and you indicate so on the enclosed form, we may contact you again about the possibility of obtaining more detailed family information.

We appreciate your help in this study and hope that you are willing to provide the information. If you do not wish to complete the questionnaire, please indicate this below and return this letter since it will make a follow-up call unnecessary. Please understand that current or future medical care at the Mayo Clinic for you and your family members will not be affected by your decision. Specifically, your care will not be jeopardized if you choose not to complete the questionnaire.
We thank you for your consideration.

Sincerely yours,

[Signature]
Lynn C. Hartmann, M.D.
Mayo Women's Cancer Program

[Signature]
John E. Woods, M.D.
Department of Surgery

[Signature]
Phillip G. Arnold, M.D.
Department of Surgery

☐ I do not wish to participate further in this survey.

KPOO
PROPHYLACTIC MASTECTOMY FOLLOW-UP STUDY
Please enter above any missing information or change any that is incorrect.

Instructions: Please check the appropriate box or fill in the blank as indicated.

Today's Date _____/_____/_____  
Month Day Year

MEDICAL HISTORY

WE ARE INTERESTED IN THE MEDICAL HISTORY AND FAMILY HISTORY 
of women who have chosen to have a prophylactic mastectomy. 
PLEASE PROVIDE US WITH THE FOLLOWING INFORMATION ABOUT THE PERSON NAMED ABOVE, 
WHOM WE REFER TO BELOW AS "SHE" OR "HER." 
IF YOU DO NOT KNOW THE INFORMATION, SIMPLY LEAVE THAT SPACE BLANK.

1. At what age did she begin menstruating?  
   __________ years

2. Did she have children?  
   1 ☐ No  2 ☐ Yes
   How old was she when her first child was born?  
   __________ years

3. Did she have any breast biopsies before her prophylactic mastectomy?  
   1 ☐ No  2 ☐ Yes
   How many breast biopsies did she have before her prophylactic mastectomy?  
   __________ Number of breast biopsies
   Did any of the biopsy results show worrisome findings?  
   1 ☐ No  2 ☐ Yes

4. Did her (blood-related) mother have breast cancer?  
   1 ☐ No  2 ☐ Yes  3 ☐ Don't know  
   If yes, in what year? __________
   What is her year of birth? __________
5. Did she have any blood-related sisters?

<table>
<thead>
<tr>
<th>1</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Yes</td>
</tr>
</tbody>
</table>

If yes, how many? ________

Have any of her sisters had breast cancer?

<table>
<thead>
<tr>
<th>1</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**SISTER #1**
If yes, in what year? ________
What is her year of birth? ________

**SISTER #2**
In what year? ________
What is her year of birth? ________

**SISTER #3**
In what year? ________
What is her year of birth? ________

**SISTER #4**
In what year? ________
What is her year of birth? ________

**SISTER #5**
In what year? ________
What is her year of birth? ________
6. Did she have any blood-related daughters?
   1 □ No  2 □ Yes
   If yes, how many? __________
   Have any of her daughters had breast cancer?
   1 □ No  2 □ Yes
   DAUGHTER #1
   If yes, in what year? __________
   What is her year of birth? __________
   DAUGHTER #2
   In what year? __________
   What is her year of birth? __________
   DAUGHTER #3
   In what year? __________
   What is her year of birth? __________
   DAUGHTER #4
   In what year? __________
   What is her year of birth? __________
   DAUGHTER #5
   In what year? __________
   What is her year of birth? __________

7. Have other blood relatives of hers, including men in the family, had breast cancer?
   1 □ No  2 □ Yes
   If yes, please list relative. ______________________________________
   ______________________________________
   ______________________________________

8. Have any of her blood relatives had ovarian cancer?
   1 □ No  2 □ Yes
9. Was she ever diagnosed with breast cancer?

1 □ No 2 □ Yes

If yes, in what year? ____________ year

In which breast? 1 □ Right 2 □ Left

What treatment did she have? ________________________________

______________________________

Did her breast cancer ever spread?

1 □ No 2 □ Yes

If yes, where?

______________________________

In what year was this discovered?

___________ year

What treatment did she have?

______________________________

______________________________

10. Did she have any other cancers?

<table>
<thead>
<tr>
<th>Cancer</th>
<th>No</th>
<th>Yes</th>
<th>What year was cancer found?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
<tr>
<td>Colon cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
<tr>
<td>Uterine cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
</tbody>
</table>

Other cancer(s) (please list)

______________________________

______________________________

______________________________

______________________________
11. After her prophylactic breast surgery, did she have any complications that required additional breast surgery?

1 □ No  
2 □ Yes

If yes, please indicate the year(s) when she needed repeat surgery and the primary reason below.

<table>
<thead>
<tr>
<th>Reason</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

12. Did she have any other difficulties with the prophylactic breast surgery that did not require additional surgery?

1 □ No  
2 □ Yes

If yes, please indicate the year(s) and the difficulty(ies) she experienced.

<table>
<thead>
<tr>
<th>Difficulty</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

13. What is your relationship to this person?

1 □ Husband  
2 □ Child  
3 □ Brother  
4 □ Sister  
5 □ Another relative  
6 □ Friend
You had a prophylactic mastectomy (preventive removal of the breast) performed by Mayo Clinic’s plastic surgeons. Dr. John E. Woods and Dr. P. G. Arnold from the Department of Surgery at Mayo and I would like to ask you for some information.

We understand that you had a prophylactic mastectomy performed at or near the time that you had your other breast removed because of cancer. Our primary purpose in contacting you at this time is to assess your particular reasons for having had a prophylactic mastectomy and to ask how your health has been following that surgery. In this packet, you will find a form containing questions about your family history of breast cancer, as well as your menstrual and reproductive history. We will also ask about any breast problems that you may have had since your prophylactic mastectomy, including the possibility of any breast cancer on that side or the need for any additional breast surgery. We will also ask you whether you have developed any other cancers.

This follow-up work that we are now doing is part of an approved Mayo Clinic study. We hope that the follow-up information learned through this study will help physicians counsel women in the future as they think about having a prophylactic mastectomy performed. As with your other Mayo Clinic records, the information that you provide us will be kept strictly confidential.

We would like to emphasize that the reason for asking these questions is not that we are concerned about silicone implants causing cancer. Most women who had prophylactic mastectomy at Mayo did so because of a concern about breast cancer. These concerns were based on a variety of reasons, including having had breast cancer in one breast, pre-cancerous change in the breast, a history of breast cancer in the family, or having had multiple prior biopsies for suspicious lumps in the past. These factors are known to increase a woman’s risk of a breast cancer to some extent. Some of these factors have also been associated with the development of other types of cancer, such as ovarian cancer or colon cancer. Thus, it is important that we learn of any additional breast cancer problem or other cancer problem that you may have had.

We would like to address the concerns that have been raised in the press about silicone implants and their possible health hazards, including links with breast cancer and several arthritis-like conditions (also called connective tissue diseases). We would like to update you regarding the status of well-controlled medical studies of patients
who have had silicone implants. A recently completed Mayo Clinic study looked at
the development of arthritis-like illnesses in Rochester-area women who had silicone-
containing implants. Mayo investigators saw no evidence for a link between these
implants and any connective tissue disease. These results have been published recent-
ly in The New England Journal of Medicine. Moreover, a Canadian group recently
studied women who had breast augmentation (or enlargement), with implant place-
ment, for any evidence of increased breast cancer risk later. In fact, these investigators
saw fewer breast cancers in women who had implants placed compared with women
in the general population (N Engl J Med, Berkel et al, June 18, 1992). This by no
means indicates that implants lower risk, but we have no reason to think that they con-
tribute to breast cancer.

We appreciate your help in this study and hope that you are willing to provide
the information. If you do not wish to complete the questionnaire, please indicate this
below and return this letter since it will make a follow-up call unnecessary. Please
understand that current or future medical care at the Mayo Clinic for you and your
family members will not be affected by your decision. Specifically, your care will not
be jeopardized if you choose not to complete the questionnaire.

If you have family members with breast cancer, and indicate so on the enclosed
form, we will be contacting you again for more detailed family information.

We thank you for your consideration.

Sincerely yours,

Lynn C. Hartmann

Lynn C. Hartmann, M.D.
Mayo Women’s Cancer Program

John E. Woods, M.D.
Department of Surgery

Phillip G. Arnold, M.D.
Department of Surgery

☐ I do not wish to participate further in this survey.

KPOO
Prophylactic Mastectomy Follow-Up Study

Survey Research Center
Please enter above any missing information or change any that is incorrect.

Instructions: Please check the appropriate box or fill in the blank as indicated.

8-13
Today's Date _____/_____/_____
Month Day Year

MEDICAL HISTORY
WE ARE INTERESTED IN THE MEDICAL HISTORY AND FAMILY HISTORY
OF WOMEN WHO HAVE CHOSEN TO HAVE A PROPHYLACTIC MASTECTOMY.

14-15
1. At what age did you begin menstruating?
   __________ years

16__
2. Have you had children?
   1 □ No  2 □ Yes
   How old were you when your first child was born?
   __________ years

19__
3. Did you have any biopsies of the noncancerous breast before your prophylactic
   mastectomy?
   1 □ No  2 □ Yes
   How many biopsies of the noncancerous breast did you have before your prophylactic mastectomy?
   __________ Number of breast biopsies
   Did any of the biopsy results show worrisome findings?
   1 □ No  2 □ Yes

23__
4. Has your (blood-related) mother had breast cancer?
   1 □ No  2 □ Yes  3 □ Don’t know
   If yes, in what year? __________
   What is her year of birth? __________
5. Do you have any blood-related sisters?

1  □  No  2  □  Yes

If yes, how many?  ________

Have any of your sisters had breast cancer?

1  □  No  2  □  Yes

SISTER #1
If yes, in what year?  ________
What is her year of birth?  ________

SISTER #2
In what year?  ________
What is her year of birth?  ________

SISTER #3
In what year?  ________
What is her year of birth?  ________

SISTER #4
In what year?  ________
What is her year of birth?  ________

SISTER #5
In what year?  ________
What is her year of birth?  ________
6. Do you have any blood-related daughters?
   1 ☐ No  2 ☐ Yes
   
   If yes, how many? ________
   Have any of your daughters had breast cancer?
   1 ☐ No  2 ☐ Yes
   
   ________________
   DAUGHTER #1
   If yes, in what year? ________
   What is her year of birth? ________
   
   ________________
   DAUGHTER #2
   In what year? ________
   What is her year of birth? ________
   
   ________________
   DAUGHTER #3
   In what year? ________
   What is her year of birth? ________
   
   ________________
   DAUGHTER #4
   In what year? ________
   What is her year of birth? ________
   
   ________________
   DAUGHTER #5
   In what year? ________
   What is her year of birth? ________

7. Have other blood relatives of yours, including men in the family, had breast cancer?
   1 ☐ No  2 ☐ Yes
   
   If yes, please list.
   __________________________
   __________________________
   __________________________

8. Have any of your blood relatives had ovarian cancer?
   1 ☐ No  2 ☐ Yes
9. You had cancer in one breast and had the other breast removed for prophylactic (preventive) purposes. On the prophylactic side, were you ever diagnosed with breast cancer?

1 □ No  
2 □ Yes  

If yes, in what year? ________ year

What treatment did you have? ________________________________

________________________________________________________________________

Did you ever have a recurrence of your breast cancer?

1 □ No  
2 □ Yes  

If yes, where?

________________________________________________________________________

In what year was this discovered? ________ year

What treatment did you have?

________________________________________________________________________

________________________________________________________________________

10. Have you had any other cancers?

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>No</th>
<th>Yes</th>
<th>What year was cancer found?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
<tr>
<td>Colon cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
<tr>
<td>Uterine cancer</td>
<td>1 □</td>
<td>2 □</td>
<td></td>
</tr>
</tbody>
</table>

Other cancer(s) (please list)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________
OUTCOMES

11. Please indicate your reason(s) for having prophylactic mastectomy.
   (Check all that apply.)
   A ☐ Cancer in the other breast
   B ☐ Family history of breast cancer
   C ☐ Lumpy breasts
   D ☐ Psychological or emotional, please specify__________________________
   E ☐ Worrisome findings on biopsy
   F ☐ Doctor’s advice
   G ☐ Other reasons not mentioned, please specify__________________________

12. From those checked above, what do you consider the three most important reasons
    for having prophylactic mastectomy? (Write the three letters in the spaces below.
    If you checked only one or two above, order them below and leave the
    remaining lines blank.)

   _______ First most important
   _______ Second most important
   _______ Third most important

13. Before your prophylactic mastectomy, what did you think
    your lifetime risk was of future breast cancer in the noncancerous breast?

   1 ☐ No risk 2 ☐ Low risk 3 ☐ Average risk 4 ☐ High risk 5 ☐ Extremely high risk

   If you were given a specific figure, please specify. __________________

14. After your prophylactic mastectomy, what did you think your risk was
    of a new breast cancer?

   1 ☐ No risk 2 ☐ Low risk 3 ☐ Average risk 4 ☐ High risk 5 ☐ Extremely high risk

   If you were given a specific figure, please specify. __________________
15. After your prophylactic breast surgery, did you have any complications that required additional breast-related surgery?

1 □ No  2 □ Yes

If yes, please indicate the primary reason for repeat surgery and the year you had the surgery.

<table>
<thead>
<tr>
<th>REASON</th>
<th>YEAR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Did you have any other difficulties with the prophylactic breast surgery that did not require surgery?

1 □ No  2 □ Yes

If yes, please indicate difficulty(ies) and year(s) experienced.

<table>
<thead>
<tr>
<th>DIFFICULTY</th>
<th>YEAR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

16. Please indicate how your prophylactic breast surgery affected you in terms of your:

   | Greatly increased | Increased | No change | Diminished | Greatly diminished |
|-------------------|-----------|-----------|-----------|-------------|------------------|
| Self-esteem       | 1 □       | 2 □       | 3 □       | 4 □         | 5 □              |
| Satisfaction with your body appearance | 1 □ | 2 □ | 3 □ | 4 □ | 5 □ |
| Feelings of femininity | 1 □ | 2 □ | 3 □ | 4 □ | 5 □ |
| Sexual relationship(s) | 1 □ | 2 □ | 3 □ | 4 □ | 5 □ |
| Emotional concern about developing breast cancer | 1 □ | 2 □ | 3 □ | 4 □ | 5 □ |
| Level of stress in life | 1 □ | 2 □ | 3 □ | 4 □ | 5 □ |
| Overall emotional stability | 1 □ | 2 □ | 3 □ | 4 □ | 5 □ |
17. Overall, how satisfied are you with your prophylactic mastectomy?

1 □ Very satisfied  2 □ Satisfied  3 □ Neither  4 □ Dissatisfied  5 □ Very dissatisfied

Please explain your reasons for your answer to this question.

________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

18. Knowing what you do now, would you choose to have prophylactic mastectomy if you had it to do over again?

1 □ Definitely would  2 □ Probably would  3 □ Unsure  4 □ Probably would not  5 □ Definitely would not

Please explain your reasons for your answer to this question.

________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

19. Knowing what you do now, would you choose to have breast reconstruction after prophylactic mastectomy if you had it to do again?

1 □ Definitely would  2 □ Probably would  3 □ Unsure  4 □ Probably would not  5 □ Definitely would not

Please explain your reasons for your answer to this question.

________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Mayo Clinic

200 First Street Southwest  Rochester, Minnesota 55905  Telephone 507 284-2511

Date

REGARDING: Ms. 8 ~

Our records indicate that you are the next of kin of Ms. 8 ~, who had a prophylactic mastectomy (preventive removal of the breast) performed by Mayo Clinic's plastic surgeons. We understand that Ms. 9 ~ is deceased. Dr. John E. Woods and Dr. P. G. Arnold from the Department of Surgery at Mayo and I would like to extend our sympathy to you and would also like to ask you for some information.

We understand that Ms. 9 ~ had a prophylactic mastectomy performed at or near the time that she had her other breast removed because of cancer. Our primary purpose in contacting you at this time is to clarify Ms. 9 ~'s reasons for having had a prophylactic mastectomy and to ask a few health-related questions pertaining to her life after her prophylactic mastectomy. In this packet, you will find a form containing questions about her family history of breast cancer, as well as her menstrual and reproductive history. We will also ask about any breast problems that she may have had following her prophylactic mastectomy, including the possibility of any breast cancer on that side or the need for any additional breast surgery. We will also ask you whether she developed any other cancers.

This follow-up work that we are now doing is part of an approved Mayo Clinic study. We hope that the follow-up information learned through this study will help physicians counsel women in the future as they think about having a prophylactic mastectomy performed. As with Ms. 9 ~'s other Mayo Clinic records, the information that you provide us will be kept strictly confidential.

If Ms. 9 ~ had family members with breast cancer, and you indicate so on the enclosed form, we may contact you again about the possibility of obtaining more detailed family information.

We appreciate your help in this study and hope that you are willing to provide the information. If you do not wish to complete the questionnaire, please indicate this below and return this letter since it will make a follow-up call unnecessary. Please understand that current or future medical care at the Mayo Clinic for you and your family members will not be affected by your decision. Specifically, your care will not be jeopardized if you choose not to complete the questionnaire.
We thank you for your consideration.

Sincerely yours,

Lynn C. Hartmann, M.D.
Mayo Women's Cancer Program

John E. Woods, M.D.
Department of Surgery

Phillip G. Arnold, M.D.
Department of Surgery

☐ I do not wish to participate further in this survey.

KPOO
Prophylactic Mastectomy Follow-Up Study

Survey Research Center
Please enter above any missing information or change any that is incorrect.

**Instructions:** Please check the appropriate box or fill in the blank as indicated.

**Today’s Date** ________________
Month   Day   Year

**MEDICAL HISTORY**
WE ARE INTERESTED IN THE MEDICAL HISTORY AND FAMILY HISTORY OF WOMEN WHO HAVE CHOSEN TO HAVE A PROPHYLACTIC MASTECTOMY.
PLEASE PROVIDE US WITH THE FOLLOWING INFORMATION ABOUT THE PERSON NAMED ABOVE, WHOM WE REFER TO BELOW AS “SHE” OR “HER.”
IF YOU DO NOT KNOW THE INFORMATION, SIMPLY LEAVE THAT SPACE BLANK.

1. At what age did she begin menstruating?
   ——— years

2. Did she have children?
   1 □ No   2 □ Yes
   ———
   How old was she when her first child was born?
   ——— years

3. Did she have any biopsies of the noncancerous breast before her prophylactic mastectomy?
   1 □ No   2 □ Yes
   ———
   How many biopsies of the noncancerous breast did she have before her prophylactic mastectomy?
   ——— Number of breast biopsies
   Did any of the biopsy results show worrisome findings?
   1 □ No   2 □ Yes

4. Did her (blood-related) mother have breast cancer?
   1 □ No   2 □ Yes   3 □ Don’t know
   ———
   If yes, in what year? ———
   What is her year of birth? ———
5. Did she have any blood-related sisters?

1. ☐ No  2. ☑ Yes

If yes, how many? ______

Have any of her sisters had breast cancer?

1. ☐ No  2. ☑ Yes

<table>
<thead>
<tr>
<th>SISTER #1</th>
<th>If yes, in what year? ______</th>
<th>What is her year of birth? ______</th>
</tr>
</thead>
<tbody>
<tr>
<td>SISTER #2</td>
<td>In what year? ______</td>
<td>What is her year of birth? ______</td>
</tr>
<tr>
<td>SISTER #3</td>
<td>In what year? ______</td>
<td>What is her year of birth? ______</td>
</tr>
<tr>
<td>SISTER #4</td>
<td>In what year? ______</td>
<td>What is her year of birth? ______</td>
</tr>
<tr>
<td>SISTER #5</td>
<td>In what year? ______</td>
<td>What is her year of birth? ______</td>
</tr>
</tbody>
</table>
6. Did she have any blood-related daughters?  
   1 □ No  
   2 □ Yes  
   If yes, how many? _________  
   Have any of her daughters had breast cancer?  
   1 □ No  
   2 □ Yes  
   **DAUGHTER #1**  
   If yes, in what year? _________  
   What is her year of birth? _________  
   **DAUGHTER #2**  
   In what year? _________  
   What is her year of birth? _________  
   **DAUGHTER #3**  
   In what year? _________  
   What is her year of birth? _________  
   **DAUGHTER #4**  
   In what year? _________  
   What is her year of birth? _________  
   **DAUGHTER #5**  
   In what year? _________  
   What is her year of birth? _________  

7. Have other blood relatives of hers, including men in the family, had breast cancer?  
   1 □ No  
   2 □ Yes  
   If yes, please list relative.  

8. Have any of her blood relatives had ovarian cancer?  
   1 □ No  
   2 □ Yes
9. She had cancer in one breast and had the other breast removed for prophylactic (preventive) purposes. On the prophylactic side, was she ever diagnosed with breast cancer?

1 □ No  
2 □ Yes

If yes, in what year? _______ year

What treatment did she have? ____________________________

______________________________

Did she ever have a recurrence of her breast cancer?

1 □ No  
2 □ Yes

If yes, where?

______________________________

In what year was this discovered? _______ year

What treatment did she have?

______________________________

10. Did she have any other cancers?

<table>
<thead>
<tr>
<th>Cancer</th>
<th>No</th>
<th>Yes</th>
<th>What year was cancer found?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian cancer</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Colon cancer</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Uterine cancer</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Other cancer(s) (please list)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Page 4
11. After her prophylactic breast surgery, did she have any complications that required additional breast surgery?

1 □ No  2 □ Yes

If yes, please indicate the year(s) when she needed repeat surgery and the primary reason below.

<table>
<thead>
<tr>
<th>Reason</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

12. Did she have any other difficulties with the prophylactic breast surgery that did not require surgery?

1 □ No  2 □ Yes

If yes, please indicate the year(s) and the difficulty(ies) she experienced.

<table>
<thead>
<tr>
<th>Difficulty</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

13. What is your relationship to this person?

1 □ Husband  2 □ Child  3 □ Brother  4 □ Sister  5 □ Another relative  6 □ Friend